Drugs that treat psoriasis and rheumatoid arthritis, or RA, by suppressing the immune system may also reduce the risk of developing diabetes, at least in people who already have one of these conditions, according to a new study in the Journal of the American Medical Association.
Moderate drinking has been linked to a variety of health benefits, including a reduced risk of heart disease, stroke, and diabetes. According to a new study, drinking alcohol may also ease the pain of -- and lower the risk of developing -- rheumatoid arthritis, a potentially crippling autoimmune disorder.
A simple blood test may allow doctors to identify a debilitating form of arthritis years before any symptoms appear, which may help to stop the disease in its tracks, new research suggests.
I am an MS [multiple sclerosis] patient and I have just about had it with my Rebif injections. I've heard about a new leukemia drug used to treat the beginning stages of MS. I think it's called Campath 1H. Are there any other medications you would recommend for early stage MS? Thank you.
Shares of Abbott Laboratories stabilized Tuesday after dropping more than 2% in the previous session when it said it would buy the industry's biggest Lasik vision equipment maker for $2.8 billion.
CNN's Dr. Sanjay Gupta reports on a new study that found cholesterol drugs may also reduce blood pressure.
Schering-Plough's stock jumped Thursday, after the drugmaker's chief executive announced he would cut 10% of its staff.
Biotech Amgen on Thursday reported an increase in earnings and a decrease in sales for the fourth quarter, beating Wall Street's forecast.
Abbott Laboratories, a maker of drugs and medical devices, reported on Wednesday a jump in sales and earnings that beat Wall Street's estimates.
The biotech Amgen reported first-quarter earnings Monday that matched expectations, though its revenue fell just short of forecasts.
Abbott Laboratories is trying to get its top-selling blockbuster drug approved for yet another use, which could lead to further sales.
A surge in Amgen Inc's fourth-quarter earnings fell short of analyst projections, but the company's sales topped expectations.
On the site of a former amusement park in a small Pennsylvania town, technicians sheathed in plastic suits labor over stainless steel fermentation tanks that look like brewery vats.
Big Pharma companies Pfizer, Lilly and Wyeth beat analysts' expectations Thursday with reports of strong gains in third-quarter earnings, though Pfizer isn't expecting annual profit growth until 2009 and is ramping up its already ambitious cost-cutting efforts.
Abbott Labs' fast-growing flagship drug Humira is grabbing market share and making money ... and now the company is trying to win the blessings of the FDA to make more.
The bell's about to sound for the next round in a patent fight that the entire pharmaceutical industry is watching.
CNNMoney: Amgen tops forecastsupdated: Thu Jul 20 2006 15:56:00
Amgen Inc. Thursday reported a surge in second-quarter earnings and sales, soundly beating Wall Street forecasts.
Investors, mark your calendars for round 2 of Big Pharma v. biotech.
A federal jury ruled that Eli Lilly & Co. infringed the patent of Ariad Pharmaceuticals with its drugs Evista and Xigris, and ordered the drugmaker to pay the Massachusetts biotech firm $65.2 million, the companies said.
Drug sales, bolstered by Medicare coverage, are projected to keep rising for the next 10 years, and biotechs are expected to get the lion's share of that increase, while the more traditional Big Pharma companies get squeezed by generic drug makers.
Bristol-Myers Squibb faces votes by FDA advisory panels on two key drugs in its pipeline, decisions that could affect the company's financial future for years to come.
Scientists using nanotechnology have devised a way of delivering cancer drugs that could make them up to 10 times more effective in combating the killer disease.
The black box label is the most potent warning in the Food and Drug Administration's arsenal, but it is not necessarily a death knell for drug sales, analysts say.
A cannabis-based painkiller for sufferers of multiple sclerosis is expected to be in Canadian pharmacies this summer, but whether it appears on U.S. pharmacy shelves is a key question.
Two drug candidates that would reduce the symptoms of rheumatoid arthritis have passed testing, announced drug manufacturers Human Genome Sciences, Roche, Genentech and Biogen Idec on Wednesday, offering hope where arthritis treatments have raised health concerns.
Johnson & Johnson says its rheumatoid arthritis drug Remicade may put patients at higher risk for lymphoma, and the company is sending out warning letters to physicians.
Fortune: Elite Factoriesupdated: Mon Sep 06 2004 00:01:00
A common thread connects this year's standouts: They all responded to crisis by radically changing the way they make things. Autoliv reprocessed its factory to fend off stiff competition in airbags...
The Empire State ballroom at the Grand Hyatt Hotel in midtown Manhattan typically serves as the setting for the kind of stuffy, state-of-a-business luncheons that are more snooze inducing than buzz...
Nokia's disappointing sales announcement and the resulting fallout in the tech sector makes a lot of nervous investors even jumpier. In particular, they fear that any earnings disappointments during the next few weeks may lead to sudden selloffs.
A cannabis-based medicine for multiple sclerosis sufferers could be available on prescription in Britain by the summer, according to its manufacturer.
Scientist Eugene Sun remembers exactly how his boss at Abbott Laboratories responded some years ago to Sun's report on his breakthrough AIDS drug, Kaletra: "I'm tired of hearing about science, I wa...
For years Amgen has seemed biotechnology's best answer to the likes of Merck--a sector leader with so much heft and momentum that you'd recommend its stock to your mom. But now making that analogy ...
Patients who want the rheumatoid arthritis-fighting drug Enbrel have to show a special card to their pharmacist, who then verifies that the patient is enrolled in the Enbrel program before dispensi...
Like any good family practitioner, Dr. Reginald Parker believes in protecting against loss. So he begins his financial exams with some basic questions: What stocks do the mutual funds own? What ind...
Fortune: THE TICKERupdated: Mon Oct 27 1997 00:01:00
FREEING A MICROSOFT SLAVE
© 2013 Cable News Network. Turner Broadcasting System, Inc. All Rights Reserved.
|